Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study

Several clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) can reduce the risk of cardiovascular events in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Recent reports indicate an underutilization of new cardiomet...

Descripción completa

Detalles Bibliográficos
Autores principales: Dzaye, Omar, Berning, Philipp, Razavi, Alexander C., Adhikari, Rishav, Jha, Kunal, Nasir, Khurram, Ayers, John W., Mortensen, Martin Bødtker, Blaha, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372305/
https://www.ncbi.nlm.nih.gov/pubmed/35966558
http://dx.doi.org/10.3389/fcvm.2022.936651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372305/
https://www.ncbi.nlm.nih.gov/pubmed/35966558
http://dx.doi.org/10.3389/fcvm.2022.936651

Ejemplares similares